**Section 690.1520 Information Required to be Reported**

a) A facility required to submit XDRO information shall report each Non-Duplicative XDRO Isolate, as specified in this Section, to the Department.

b) The information to be reported shall be provided in a format designated by the Department and may be submitted either by direct electronic transmission or entry into a website. The information to be reported is divided into four subject areas, each containing a particular set of information. The four subject areas of the incidence report shall include the following:

1) Patient Data and Address − patient's full name (including maiden name, when applicable and available), last four digits of the Social Security number (if available), telephone number and residential address, including street address, city, county, state and postal code;

2) Personal Data − patient's birth date, sex, race and ethnicity (if available);

3) Culture Data − specimen collection date, specimen source, isolate genus, isolate species, specific carbapenemase name (if known), antibotic resistance criteria for entry into the Registry; and

4) Facility Data − facility identification number provided by the Department, the medical record number, and the date of admission.

c) Each XDRO report shall be submitted within seven calendar days after the test result is finalized.

d) Upon request from the Department or the Department's designee, each reporting facility shall provide access to additional information from all medical, pathological and other pertinent records related to the XDRO diagnosis, treatment, and follow-up for the purposes of infection control and quality improvement.

e) Beginning September 1, 2013, reporting facilities shall report carbapenem-resistant enterobacteriaceae (e.g., E. coli, Klebsiella species, Enterobacter species, Proteus species, Citrobacter species, Serratia species, Morganella species, or Providentia species) based on laboratory test results:

1) Molecular test (e.g., polymerase chain reaction (PCR)) specific for carbapenemase;

2) Phenotypic test (e.g., Modified Hodge) specific for carbapenemase production; or

3) For E. coli and Klebsiella species only: nonsusceptible to one of the following carbapenems: doripenem, meropenem, or imipenem and resistant to all of the following third generation cephalosporin that were tested: ceftriaxone, cefotaxime, and ceftazidime.

(Source: Added at 37 Ill. Reg. 12063, effective July 15, 2013)